Warfarin and Ledipasvir: Interaction Details

Brand names
Warfarin
CoumadinJantoven
Dr. Brian Staiger, PharmD, BCPS

Medically reviewed by ⁠

Also reviewed by the HelloPharmacist Editorial Team Updated AI-assisted Details about this page
Share

Share this interaction

Warfarin

Brand names
  • Coumadin
  • Jantoven

Ledipasvir

We don't have a separate drug information page for Ledipasvir. The FDA's drug directory lists it as part of Harvoni (ledipasvir and sofosbuvir). Read the Ledipasvir and Sofosbuvir drug information page → Have a question about Ledipasvir? Ask a pharmacist, free →

What Happens When You Take Warfarin With Ledipasvir

What can happen when they are taken together (rated Major)

Fluctuations in

Interaction Deep Dive

A note from Dr. Brian Staiger If you’re a patient, this deep dive may be too technical, or bore you (or both). Read the plain-language explanation →

Giving warfarin together with direct-acting antivirals for hepatitis C virus (HCV) infection, with or without ribavirin, can cause INR values to fluctuate.1 A cohort study found that adding any of several HCV combination regimens to stable warfarin therapy significantly reduced the dose-response to warfarin, and subtherapeutic INR values rose by more than 2-fold.

When ribavirin was included, the dose response fell further.5 Close INR monitoring is recommended both during and after HCV treatment.34

The Warfarin and Ledipasvir Interaction, Explained

If you take warfarin and are treated for hepatitis C with a medicine containing ledipasvir, your (the blood test that shows how well warfarin is thinning your blood) may go up and down more than usual. In one study, people on steady warfarin had more than twice as many INR readings that were too low (meaning less protection against clots) once hepatitis C treatment began. The exact reason isn't known, and this is based on limited, theoretical data.

Keep taking both medicines as prescribed. Let your care team know you take warfarin, and expect more frequent INR checks during and after hepatitis C treatment. They can adjust your warfarin dose as needed.

Effect: Labile when direct-acting antivirals (DAAs, with or without ribavirin), including ledipasvir-containing regimens, are added to stable warfarin therapy.

  • Mechanism: Unknown. Changes in function and coagulation during HCV may contribute (not established).
  • Direction/magnitude: In a cohort study, warfarin dose-response decreased significantly, with a greater than 2-fold increase in subtherapeutic INR values. Ribavirin further reduced dose-response.
  • Onset: Unspecified. Evidence: Theoretical/observational. Warfarin has a , so small shifts matter.
  • Management: Monitor INR frequently during and after HCV therapy and adjust the warfarin dose individually.

See the 5 references behind this explanation ↓

From the HelloPharmacist Pharmacy Team

AI-assisted: written with AI from this pair’s record in our interaction database, and reviewed by the HelloPharmacist pharmacy team. Written .

How we build these pages · How we use AI · Our editorial policy

Why Warfarin and Ledipasvir Interact

The likely mechanism

Unknown

“Unknown” here means the studies and labels behind this record do not say how the interaction happens. It does not mean the interaction is unlikely.

When two medicines can each cause the same effect, here bleeding, taking them together can add to it. That is often the reason for an interaction like this one, though the sources do not confirm it for this pair.

How Drug Interactions Work Six short figures, about a minute: how one drug can raise or lower another’s level, or add to or cancel its effect. See how it works 

How to Manage the Warfarin and Ledipasvir Interaction

Your care team typically manages this with frequent monitoring while you are on hepatitis C treatment and after it finishes. Your warfarin dose may need to be adjusted and individualized by your care team based on those results.

  • Keep taking both medicines as prescribed, and do not change your warfarin dose on your own.
  • Tell your pharmacist and prescriber before starting or finishing hepatitis C treatment.
  • Keep every scheduled INR appointment.
  • Report unusual bruising, bleeding, or signs of a clot (such as sudden swelling, leg pain, or shortness of breath) right away.

Management is individual — confirm any change with your pharmacist or prescriber.

Questions for Your Pharmacist

  • Does my dose of Warfarin or Ledipasvir need adjusting while I take them together?
  • What symptoms should prompt me to call you or my prescriber right away?
  • Does the timing of my doses matter for this combination?
  • Is there another option that avoids this interaction?

Literature Reports

1 report from the published literature. Each one is headed by the title of the published study it comes from.

What these reports are. Short summaries of published evidence on this combination: clinical studies, case reports and, at times, the FDA prescribing information for one of the drugs. They support this interaction, but it does not rest on them alone. It can also rest on prescribing information not summarized here, or on what is expected from how these two drugs, and others in their drug classes, are known to work.

  1. Report 1 · Study title

    Evaluation of a potential interaction between new regimens to treat hepatitis C and warfarin

    In a cohort study (N=271) of patients on stable warfarin therapy who received one of several direct-acting antiviral regimens (with or without ribavirin) for hepatitis C virus (HCV) infection, warfarin dose-response, measured by the warfarin sensitivity index (WSI; divided by average daily warfarin dose), fell significantly by 23%. Across the 12-week course of HCV therapy, the overall WSI declined from 0.53 to 0.39.

    Significant reductions from baseline in WSI were seen with the combination of sofosbuvir and ledipasvir (15.1%), the combination of sofosbuvir and simeprevir (12.2%), and the combination of ombitasvir, paritaprevir, ritonavir, and dasabuvir (32%). The reduction seen with sofosbuvir monotherapy (9.4%) was not significant.

    ribavirin produced a further significant WSI decrease of 16.9%. The greatest effect (49%) occurred with the combination of ombitasvir, paritaprevir, ritonavir, and dasabuvir plus ribavirin.

    Subtherapeutic INR values were found in 26% of patients evaluated during the 12 weeks before the study and in 58% during the 12 weeks of HCV treatment. The mean weekly warfarin dose rose from 39.9 mg when HCV treatment began to a mean of 46 mg when HCV therapy ended.5

Warfarin and Ledipasvir: Common Questions

How serious is the Warfarin and Ledipasvir interaction?

It is rated major. Potentially serious — often needs a change or close monitoring.

How is the Warfarin and Ledipasvir interaction managed?

Your care team typically manages this with frequent monitoring while you are on hepatitis C treatment and after it finishes. Your warfarin dose may need to be adjusted and individualized by your care team based on those results. Keep taking both medicines as prescribed, and do not change your warfarin dose on your own. Tell your pharmacist and prescriber before starting or finishing hepatitis… Management is individual — always follow your own care team's guidance.

How quickly could this interaction happen?

The documented onset is "unspecified". The timing of this interaction is not well characterized.

How strong is the evidence for this interaction?

The evidence is graded "theoretical". Expected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study.

Ask About the Warfarin and Ledipasvir Interaction

Ask in your own words about taking Warfarin and Ledipasvir together. The answer comes from this page’s interaction record and both drugs’ own information.

This box answers questions about this one combination only. For anything else about either drug, open its drug information page or ask a pharmacist.

Try:

AI answers from this page’s record and both drugs’ information, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.

References (5)

  1. Product Information: VIEKIRA XR oral extended-release tablets, dasabuvir, ombitasvir, paritaprevir, ritonavir oral extended-release tablets. AbbVie Inc (per manufacturer), North Chicago, IL, 2017.
  2. Product Information: VIEKIRA PAK oral tablets, ombitasvir, paritaprevir, ritonavir, dasabuvir oral tablets. AbbVie Inc (per FDA), North Chicago, IL, 2017.
  3. Product Information: DAKLINZA(TM) oral tablets, daclatasvir oral tablets. Bristol-Myers Squibb Company (per manufacturer), Princeton, NJ, 2017.
  4. Product Information: SOVALDI(R) oral tablets, sofosbuvir oral tablets. Gilead Sciences, Inc. (per FDA), Foster City, CA, 2017. DailyMed
  5. DeCarolis DD, Westanmo AD, Chen YC, et al: Evaluation of a potential interaction between new regimens to treat hepatitis C and warfarin. Ann Pharmacother 2016; 50(11):909-917. PubMed
Was this write-up helpful?

Other Serious Interactions of Warfarin and Ledipasvir

Also serious with Warfarin

Also serious with Ledipasvir

These Medications Also Interact With Supplements

Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:

With Warfarin

Check everything you take with our drug–supplement interaction checker.

Still Have Questions About This Combination?

Every question gets a real answer from a licensed pharmacist — free, as soon as they can.

About This Library

Built in-house, documented one interaction at a time. Our interaction database is not a complete list of every known interaction: a combination that isn't listed here hasn't been documented by us yet, which never means it's safe. Checking everything you take at once? Ask your pharmacist to review your full medication list. How we build and review it →

What Each Rating Means

Severity Levels

  • Contraindicated These should generally not be used together.
  • Major Potentially serious — often needs a change or close monitoring. This interaction.
  • Moderate Can be significant — usually manageable with monitoring.
  • Minor Usually limited clinical impact.

Evidence Grades

  • EstablishedWell documented — supported by controlled studies or strong clinical data.
  • ProbableGood supporting evidence, though not definitively proven.
  • SuspectedSome evidence suggests this interaction, but it is not well established.
  • PossibleLimited or conflicting evidence; the interaction may occur.
  • TheoreticalExpected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study. This interaction.

How Soon It Shows

  • RapidEffects can appear quickly, often within about 24 hours of combining the drugs.
  • DelayedEffects tend to build up gradually over days to weeks.
  • UnspecifiedThe timing of this interaction is not well characterized. This interaction.

Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.

Back to the answer
This information is for education, not a substitute for professional medical advice. Do not start, stop, or change any medication without talking to your pharmacist or prescriber.